MDS-157 Luspatercept与Epoetin Alfa (EA)治疗需要红细胞(RBC)输血的促红细胞生成素(ESA)初始低风险骨髓增生异常综合征(LR-MDS)患者的贫血:来自III期COMMANDS研究的数据

{"title":"MDS-157 Luspatercept与Epoetin Alfa (EA)治疗需要红细胞(RBC)输血的促红细胞生成素(ESA)初始低风险骨髓增生异常综合征(LR-MDS)患者的贫血:来自III期COMMANDS研究的数据","authors":"G. Garcia-Manero, U. Platzbecker, V. Santini, A. Zeidan, P. Fenaux, R. Komrokji, J. Shortt, D. Valcárcel, A. Jonášová, S. Dimicoli-Salazar, I. Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, A. C. Giuseppi, S. Kreitz, Veronika P. Pozharskaya, K. Keeperman, S. Rose, J. Shetty, Sheida Hayati, S. Vodala, Andrius Degulys, S. Paolini, T. Cluzeau, M. D. Porta","doi":"10.1016/s2152-2650(23)01169-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"69 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study\",\"authors\":\"G. Garcia-Manero, U. Platzbecker, V. Santini, A. Zeidan, P. Fenaux, R. Komrokji, J. Shortt, D. Valcárcel, A. Jonášová, S. Dimicoli-Salazar, I. Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, A. C. Giuseppi, S. Kreitz, Veronika P. Pozharskaya, K. Keeperman, S. Rose, J. Shetty, Sheida Hayati, S. Vodala, Andrius Degulys, S. Paolini, T. Cluzeau, M. D. Porta\",\"doi\":\"10.1016/s2152-2650(23)01169-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"69 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01169-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01169-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}